Double umbilical cord blood transplantation is increasingly applied in the treatment of adult patients with high-risk hematological malignancies and has been associated with improved engraftment as compared to single unit cord blood transplantation. The mechanism of improved engraftment is however still incompletely understood as only one unit survives. In this multicenter phase II study we evaluated engraftment, early chimerism, recovery of different cell lineages and transplant outcome in 53 patients receiving a double cord blood transplantation preceded by a reduced intensity conditioning regimen. Primary graft failure occurred in 1 patient. Engraftment was observed in 92% of patients with a median time to neutrophil recovery of 36 days (range, 15-102). Ultimate single donor chimerism was established in 94% of patients. Unit predominance occurred by day 11 post transplant and early CD4+ T-cell chimerism predicted for unit survival. Total nucleated cell viability was also associated with unit survival. With a median follow up of 35 months (range, 10-51), the cumulative incidence of relapse and non-relapse mortality at 2 years were 39% and 19%, respectively. Progression-free survival and overall survival at 2 years were 42% (95% confidence interval , 28-56) and 57% (95% confidence interval, 43-70), respectively. Double umbilical cord blood transplantation preceded by a reduced intensity conditioning regimen using cyclophosphamide/fludarabine/TBI 4 Gy results in a high engraftment rate with low non-relapse mortality. Moreover, prediction of unit survival by early CD4+ lymphocyte chimerism might suggest a role for CD4+ lymphocyte mediated unit-versus-unit alloreactivity. www.trialregister.nl NTR1573.
Introduction
Umbilical cord blood is a valuable alternative stem cell source for patients in need of an allogeneic stem cell transplantation (SCT) but lacking a matched unrelated donor. However, cell dose is the major limitation in single umbilical cord blood transplantation (UCBT) for adult patients, as the small number of hematopoietic progenitor cells in a single umbilical cord blood unit (CBU) is associated with a protracted or insufficient neutrophil recovery [1] [2] [3] [4] [5] .
The lack of CBUs containing a sufficient cell dose has been overcome with the development of the double UCBT concept 6 . However, the higher cell dose of 2 units insufficiently explains the better engraftment, because one CBU ultimately survives. Recently it has been shown that the outcome of single UCBT using units with adequate cell dose is comparable to double UCBT 7 . Moreover, it has been suggested that double UCBT results in less relapse as compared to single UCBT 8 but a recent report did not confirm that conclusion 7 . These observations suggest a facilitating role for the nonengrafting unit in transplant outcome. However, neither the mechanism of unit predominance and survival nor the presence and significance of unit-versus-unit interactions have consistently been demonstrated yet. Consequently, optimal selection criteria for a double unit combination have not been clearly defined.
Various reduced intensity conditioning (RIC) regimens have been developed to extend the use of UCBT in adult patients [9] [10] [11] [12] [13] [14] [15] [16] . To date, the regimen as proposed by the Minneapolis group yields superior results regarding neutrophil recovery and non-relapse-related mortality (NRM). Moreover, it was reported that UCBT preceded by that nonmyeloablative (NMA) regimen resulted in a similar survival as compared to RIC peripheral blood stem cell (PBSC) transplantation using an 8/8 or 7/8
HLA-matched donor 17 .
The benefit of antithymocyte globulin (ATG) in RIC regimens preceding UCBT is still unclear 18 .
ATG might prevent rejection especially in patients who did not receive chemotherapy within 3 months before transplantation 9, 18 . On the other hand, ATG induces in vivo T-cell depletion of the graft. T-cell depletion of CBUs might interfere with engraftment potential, thereby resulting in mixed chimerism.
Persistent dual donor chimerism after double UCBT has been attributed to the use of ATG as well 19, 20 (own unpublished data). Furthermore, delayed immune reconstitution may potentially lead to more infections and higher non-relapse mortality (NRM). A high incidence of Epstein-Barr virus (EBV)-related complications was reported after ATG-containing NMA conditioning regimens 15, 21, 22 .
We hypothesized that a 4 Gy total body irradiation (TBI) based conditioning regimen without the use of ATG would result in rapid and complete donor chimerism with early T-cell recovery by inducing sufficient recipient immune suppression to prevent rejection without a negative effect on CBU engraftment potential. Therefore, in this prospective study we evaluated clinical outcome of double UCBT preceded by a RIC regimen consisting of cyclophosphamide, fludarabine and 4 Gy TBI (cy/flu/TBI 4 Gy). In addition, we analyzed the pattern of early chimerism and the influence of graft characteristics on engraftment kinetics and unit survival.
Methods

Patients and cord blood units
Patients were eligible for inclusion if they met the following criteria: (1) 
Study end-points
The primary end-point of the study was the proportion of patients with primary graft failure, defined as persistent cytopenia and BM hypoplasia with < 10% donor hematopoiesis at day +60.
Secondary endpoints included the time to PB cell recovery, cumulative incidence of acute and chronic GVHD, non-relapse mortality (NRM), progression-free survival (PFS) and overall survival (OS).
Statistical analysis
This study was designed as a non-randomized, prospective, multicenter phase II trial, following an optimal Simon 2-stage design 23 . The primary end-point was defined as the proportion of patients with primary graft failure. A true percentage of 25% patients with a primary graft failure at day 60 post-transplant would be considered too high, while 10% or less would be desirable. With α = 0.10 and β = 0.20, this would imply a sample size of 34 patients. However, in order to overcome dropout, 40 patients were planned to be included. Adverse events and infections were scored according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. PFS and OS were estimated by the Kaplan-Meier method, and 95% confidence intervals (CI) were constructed. KaplanMeier survival curves were generated to illustrate PFS and OS. The cumulative incidences of PD and NRM were calculated using competing risk analyses.
Further exploratory analyses were also performed. The Wilcoxon matched-pairs signed rank test was used to evaluate variables associated with unit dominance. Univariate Cox regression analysis was performed to study the association of unit characteristics of the engrafting unit with outcome. All reported P values are 2-sided, and a significance level α=0.05 was used, without correction for multiple testing. Table 1 ). The median numbers of unit-recipient HLA class I (A, B, C) and class II (DRB1, DQB1, DPB1) allele mismatches were 2 (range, 0-6) and 3 (range, 0-5), respectively.
Results
Patient and CBU characteristics
Killer-cell immunoglobulin-like receptor ligand mismatches 24 were absent in 43% and 45% of unit versus recipient and unit versus unit combinations, respectively. The median follow-up of surviving patients was 25 months (range, 9-49).
Hematological recovery
Primary graft failure occurred in 1 patient (2%). The cumulative incidence of neutrophil recovery at day +60 and +90 was 83% and 92%, respectively ( Figure 1A ). The cumulative incidence of engraftment was 92% with a median time to neutrophil recovery of 36 days (range, 15-102). Three patients did not meet the criteria for engraftment at the time of death due to persistent pancytopenia (n=1) or because the neutrophil count had not been measured yet despite a leukocyte count of above 2 x 10 9 /l (n=2). However, single donor chimerism had been established in all 3 patients. Secondary graft failure occurred in 1 patient at 3 months post-transplant. The cumulative incidence of platelet recovery to 20, 50 and 100x10 9 /l at day +60 was 66%, 23% and 11%, respectively ( Figures 1B-1D ).
Neutrophil and platelet recovery were not associated with allele level or class II unit-unit HLA-match (Table 2) .
A higher TNC content of the surviving unit was associated with a faster neutrophil recovery (32 vs 39 days, p= 0.04) ( Table 2) . A higher CFU-GM dose of the surviving unit resulted in a time to neutrophil recovery of 32 days as compared to 39 days with a CFU-GM below the median, however this did not reach statistical significance. Total TNC infused was not associated with neutrophil recovery (data not shown).
NK-cells recovered to normal values within 2 months. B-cells recovered to normal values after
6 months. T-cell recovery was slow whereby absolute cell counts reached the lower limits of normal values by 12 months. Strikingly, CD4+ T-cell recovery was somewhat more rapid than CD8+ T-cell recovery during the first months post transplant with a median cell count at 3 and 6 months of 0.18x10 9 /l and 0.27x10 9 /l, respectively ( Figure 2 ).
Chimerism assessment
Complete single donor chimerism (STR-PCR) was present in 77% of patients at day +32
( Figure 3A ), increasing to 94% at 3 months. Complete donor chimerism with presence of both units was observed in 4 (9%) patients at day +32. However, 1 unit was predominant at that time point and single donor chimerism was established at day +60 in 3 of these patients. They had received units with an 8/12 (n=1; 4 mismatches at HLA class II), 11/12 (n=2; mismatch at HLA-DPB1) or 12/12 (n=1) unit-unit match. Double donor chimerism without a clear unit predominance persisted until relapse disease beyond day +180 in the patient who had received a 12/12 matched unit combination. Mixed chimerism was present in 5 patients (11%) at day +32 and persisted in 1 patient beyond day+90.
Results of T-cell chimerism were concordant with results of unseparated PB in the majority of patients at all time points (data not shown).
Early chimerism was analyzed by STR-PCR in 44 patients ( Figure 3B ). Median 40% (range, 0-100) of PB cells originated from the ultimately surviving unit at day +11 increasing to 82% (range, 0-100) at day +18. Predominance of the ultimately surviving unit over the non-engrafting unit was present in 78% and 89% of patients at day +11 and +18, respectively. The non-engrafting unit had completely disappeared beyond day 18 in most patients. Recipient hematopoiesis did not substantially contribute to PB cell recovery as recipient PB cells had disappeared before neutrophil recovery.
Simultaneous 3-donor-origin detection of leukocyte subpopulations based on HLA mismatches using HLA-mAbs was possible in 10 patients. Results were reported earlier as a part of a larger patient group 25 . In short, at day +11, the percentage of cells derived from the surviving unit within CD4+ T-cells, CD8+ T-cells, NK-cells, monocytes and granulocytes in PB was median 89% (range, 46-100), 98% (range, 66-100), 61% (range, 36-93), 42% (range, 9-84) and 19% (range, 0-98), respectively (results not shown). Ultimate unit survival was predicted by chimerism within CD4+ and NK cell subsets in 89% (8/9 evaluable patients) and 89% (8/9 evaluable patients) of patients, respectively, at this time point. CD8+ T-cell numbers were below the detection limit in 7/10 patients precluding the prediction of donor chimerism, but chimerism in the 3 remaining patients was concordant with ultimate graft predominance.
Absolute cell counts, as measured by the different participating transplant centers, showed a high inter-laboratory variation. Therefore, the analyses regarding absolute cell counts were performed separately on a subgroup of 33 patients from a single transplant center as well. Analyses of TNC viability and CFU-GM were only performed within that subgroup. TNC viability was associated with unit survival (median 64.5% in surviving vs 56.5% in non-engrafting units, p= 0.003) ( Table 3 ). Neither absolute counts of TNC, CD34+ cells, T-, B-and NK-cells nor unit-recipient allele level HLA match degree were associated with unit survival.
Patient outcome
EBV reactivation requiring therapy and EBV-PTLD developed in 10% and 4% of EBV serostatus positive patients, respectively. CMV reactivation requiring therapy occurred in 40% of CMV serostatus positive patients while CMV disease was not observed. Viral upper respiratory infections were reported in 26% of patients whereas BK virus reactivation and infections with norovirus or adenovirus were reported in 19%, 6% and of patients, respectively.
The cumulative incidence of NRM at day +90 was 9% (standard error (s.e.) 4%); the 2 year NRM was 19% (s.e.5%) ( Figure 4A ). Causes of death were infections (viral and fungal infection, n=1; bacterial sepsis, n=1), infections in a GVHD setting (viral and/or fungal infection, n=3), multi-organ failure (n=2), cardiac complications (n=2), secondary graft failure (n=1) and leukoencephalopathy (n=1).
The cumulative incidences of acute GVHD grades II-IV and grades III-IV at day 90 were 53%
and 11%, respectively. The cumulative incidence of chronic GVHD at 1 year was 38%, whereas this was 19% for extensive chronic GVHD. The cumulative incidence of relapse or progression of disease was 23% (s.e.6%) at 1 year and 39% (s.e.7%) at 2 years ( Figure 4A ). The probability of PFS and OS at 2 years were 42% (95% CI, 28-58%) and 57% (CI, 43-70%), respectively ( Figures 4A and 4B) . A HCT-CI score of > 2 was associated with OS (HR 3.14, 95% CI 1.42-6.93, p= 0.006).
Absolute cell counts, TNC viability and CFU-GM of the surviving unit were not associated with NRM, relapse, PFS and OS nor were 6 loci (A, B, C, DRB1, DQB1, DPB1) or HLA class II (DRB1, DQB1, DPB1) allele level match degree (Table 2 ). However, a higher unit-recipient HLA-A,-B,-C,-DRB1 allele level match degree (≥6/8) was associated with higher relapse, but not with overall survival.
A better (≥5/6) HLA-A, -B, -DRB1 unit-unit match (selection criteria) was associated with lower NRM but not with time to neutrophil recovery, relapse or PFS ( Table 2 ). The lower NRM translated into a trend for better OS (92% vs 57% at 1 year and 75% vs 51% at 2 years, respectively). Apart from HLA-matching, also mismatching for NK inhibitory receptors (KIR) was evaluated for possible association with relapse. However, KIR mismatching for surviving units with the recipient (in the graftversus-leukemia (GVL) direction) appeared not significantly associated with relapse (HR=1.78 (0.52-6.04), p=0.36).
Discussion
We studied the outcome and early chimerism of double UCBT preceded by a RIC regimen using cyclophosphamide, fludarabine and 4 Gy TBI. This regimen resulted in a high engraftment rate, a low NRM and approximately 20% of chronic extensive GVHD.
Complete single donor chimerism was observed within 1 month in bone marrow as well as in unseparated peripheral blood and in PB T-cells in most patients, which is faster than reported after a ATG-containing RIC regimen 12, 15, 22, 26 . Early establishment of complete donor chimerism might be favorable as persistent mixed chimerism after RIC SCT is associated with relapse and rejection 27 .
Graft predominance was established within 11 days in most patients. In a previous study in a subcohort of these patients using flow cytometry with HLA-mAbs 25 we observed that early CD4+ Tlymphocyte chimerism was predictive for ultimate graft predominance, which may suggest a role for Only one primary graft failure was observed, but the time to neutrophil recovery was prolonged (36 days) as compared to other reports regarding RIC 12-16, 33, 34 or myeloablative regimens 6, 8, 33, 35 . Our chimerism results revealed that recipient hematopoiesis disappeared early after transplantation and thereby did not contribute to neutrophil recovery, which differs from less myelotoxic conditioning regimens. In contrast to most other reports, G-CSF was not applied in this study. The duration of neutropenia may largely be attributed to the lack of G-CSF, as Ponce et al. reported a median time to neutrophil recovery of 26 days using a comparable 4 Gy based RIC regimen supported with G-CSF 34 while use of the less myelotoxic cyclophosphamide/fludarabine/ TBI 2 Gy regimen with G-CSF resulted in a median time to neutrophil recovery of 9-12 days 13, 17 . In our study, the prolonged neutropenia resulted in a protracted hospital stay but did not result in early NRM.
Despite the lack of ATG as well as the expected higher toxicity of a 4 Gy TBI dose, rates of NRM and GVHD were similar to those reported by the Minneapolis group, using a lower TBI dose with or without ATG 13, 17 . In addition, the incidence of EBV-PTLD was low, in contrast to that reported after ATG-containing RIC regimens 12, 15, 21, 22, 26 . These findings suggests that ATG can be safely omitted using our 4 Gy based conditioning regimen. An ATG-free conditioning regimen might permit the development of unit-versus-unit allo-immune reactions thereby leading to a rapid establishment of single donor chimerism and disease control. Moreover, suppression of transient autologous recovery by 4 Gy TBI might lead to a stronger antileukemic effect as well.
We did not find an association between graft characteristics and unit survival except post-thaw TNC viability. To date, TNC, CD34+ cell content and HLA match grade have not been found predictive for unit survival, but CD3+ cell dose 36, 37 and CD34+ cell viability 36, 38 may be associated with unit predominance. Our observation that post-thaw TNC viability was associated with unit survival supports the hypothesis that, apart from immunological unit-vs-unit reactions, unit quality is important in unit survival.
We observed a higher relapse rate if the surviving unit had a ≥6/8 unit-recipient match compared to a ≤5/8 HLA match. Recently, an association between allele level HLA match degree and risk of NRM but not with relapse after single unit myeloablative UCBT was reported 39 . Moreover, it was suggested that allele level HLA match of the surviving unit was associated with GVHD severity in double UCBT preceded by an ATG-free conditioning regimen 40 . Malignant cells express class II HLAantigens and are therefore susceptible targets for CD4+ T-cells. The lower relapse rate in our ≤ 5/8 matched transplants may thus be explained by a higher frequency of alloimmune CD4+ T-cells in the engrafting unit resulting in a graft-versus-disease reaction. In double UCBT, the transient presence of the non-engrafting unit might fuel that allo-immune reaction of higher mismatched units leading to a better disease control at the cost of more severe GVHD.
In conclusion, double UCBT after RIC using cy/flu/TBI 4 Gy was associated with a high engraftment rate, but slow recovery. However, the protracted neutropenic phase was not associated with NRM. Despite a relatively slow recovery, rapid establishment of unit predominance leading to single donor chimerism was observed in 94% of patients. These results suggest that G-CSF is not necessary for engraftment and establishment of chimerism. Furthermore, early CD4+ T-lymphocyte chimerism was predictive for ultimate graft predominance, suggesting a role for HLA class II in unit-versus-unit reactions, leading to single donor chimerism, which has provided a basis for an ongoing, prospective study.
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Progression-free survival (PFS) was calculated as the time from transplantation until progression/relapse (PD) or non-relapse mortality (NRM), whichever came first. Overall survival (OS) was determined from transplantation until death from any cause. Patients still alive at the date of last contact were censored.
Transplant procedures
The conditioning regimen consisted of cyclophosphamide (60 mg/kg) at day -7, fludarabine (40 mg/m 2 ) at days -6 to -3 and TBI 2 Gy at days -2 and -1. All patients received graft-versus-host disease (GVHD) prophylaxis consisting of mycophenolate mofetil (MMF) 3 times a day from day 0 until day +30 and cyclosporin A, twice daily, from day -5 to at least day +90. Patients were hospitalized in laminar air flow rooms until neutrophil counts had reached 0.2 x 10 9 /l on two consecutive days.
Beginning at day -7 until neutrophil recovery antibacterial and antifungal prophylaxis were given according to local protocols. Both units were infused at one day with a 2 hours' time interval in between in 6 patients. The majority of patients received their grafts on 2 subsequent days. This change in policy was made after several infusion reactions had been observed. Units were washed before infusion if the prefreeze RBC count exceeded 150 x 10 9 per bag for major ABO-incompatible products or 300 x 10 9 for all other units. RBC-depleted units were infused immediately after a directthaw procedure at the bedside. From day 0 until day +15 i.v. streptococcal prophylaxis was added. As from day 0 antiviral prophylaxis (valaciclovir) was given. Prophylaxis for Pneumocystis jirovecii 
Analysis of early chimerism in leukocyte subsets
Early chimerism in leukocyte subsets was analysed by the use of HLA-specific monoclonal antibodies (HLA-mAbs) in a subgroup of patients as described before 1 . Briefly, flow cytometry using HLA-mAbs was performed on PB if the presence of antigen mismatches between recipient and cord blood units allowed for the simultaneous detection of both recipient-derived and CBU-derived PB cells.
This subgroup consisted of all patients that qualified for simultaneous 3 party detection after transplantation. Results were reported before as a part of a larger cohort of analysed patients 1 .
Additional analyses of cord blood units
